Abstract

Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive. To address this, inhibitory receptors were blocked and regulatory T cells depleted in acutely Friend retrovirus-infected mice. CIT resulted in a dramatic expansion of cytotoxic CD4+ and CD8+ T cells and a subsequent reduction in viral loads. Despite limited viral replication, mice developed fatal immunopathology after CIT. The pathology was most severe in the gastrointestinal tract and was mediated by granzyme B producing CD4+ and CD8+ T cells. A similar post-CIT pathology during acute Influenza virus infection of mice was observed, which could be prevented by vaccination. Melanoma patients who developed immune-related adverse events under immune checkpoint CIT also presented with expanded granzyme-expressing CD4+ and CD8+ T cell populations. Our data suggest that acute infections may induce immunopathology in patients treated with CIT, and that effective measures for infection prevention should be applied.

Highlights

  • Cytotoxic CD8+ T cells are crucial for the control of tumor cells and acute viral infections

  • Combination immunotherapy (CIT) directed against checkpoint mechanisms has been approved for the therapy of cancers and is proposed for the treatment of chronic infections

  • We show that acute viral infections (Friend retrovirus and Influenza virus) posed a significant threat during CIT in mice

Read more

Summary

Introduction

Cytotoxic CD8+ T cells are crucial for the control of tumor cells and acute viral infections. During chronic viral infections, like HIV or HCV, these cells become dysfunctional or “exhausted” [1]. The studies of Dr Ahmed‘s group [2] demonstrated that signaling from the programmed death receptor (PD-1) expressed on LCMV specific CD8+ T cells is a central mechanism regulating the development of T cell dysfunction during chronic viral infections. Blocking the PD-1/PD-L1 interaction and/or other inhibitory receptors, like Tim-3, results in improved control of chronic infections. These studies and previous work in tumor mouse models [3,4] paved the way to develop new immunotherapies against certain human cancers, as T cell dysfunction is a hallmark of many malignant diseases [5]. The clinical success of these immunotherapies has been outstanding for some cancer entities treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, Hodgkin lymphoma and others [6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call